Varian's Halcyon receives Brazilian market clearance
Varian Medical Systems' Halcyon radiation therapy system has received clearance...Read more on AuntMinnie.comRelated Reading: Oncology Services installs Varian radiotherapy system Varian opens new regional center in Brazil Varian secures Japanese clearance for Halcyon Varian names new chief people officer Varian's fiscal 2017 results hold steady
Each year, MD+DI’s editors gather to choose which company should be named the Medtech Company of the Year, and it’s always a heated debate. This year, we named nine finalists, but the decision to crown Abbott as our 2017 Medtech Company of the Year was unanimous. Our readers, however, had a different opinion. While MD+DI’s editors chose Abbott for its ability to rise above challenges, Bigfoot Biomedical was the favorite among our readership. The Milpitas, CA-based firm is amalgamating other companies’ hardware plus its own software and algorithms to craft an artificial pancreas for patients with dia...
Almost 10% of women don't receive radiation therapy after breast conservation...Read more on AuntMinnie.comRelated Reading: ASTRO: Breast radiation 'less scary' than expected JCO releases new sentinel node biopsy guidelines ASTRO: Radiation boost cuts local recurrence in DCIS patients Choosing Wisely boosts use of short-course breast radiation therapy
Condition: Pancreatic Cancer Interventions: Radiation: Radiation; Drug: SHR-1210 Sponsors: Shixiu Wu; Jiangsu HengRui Medicine Co., Ltd. Recruiting
CONCLUSION: Systemic therapy after either SRS or WBRT radiotherapy may significantly reduce the risk of mortality of patients with 1-3 BMs. PMID: 29237923 [PubMed - in process]
We report a case of a 65-year-old man with hepatocellular carcinoma who bled massively after a hepatic Yttrium-90 radioembolization procedure (Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres [SIRTex]). An acquired deficiency of factor VIII was diagnosed and successfully treated with recombinant activated factor VII and immunosuppression.
CONCLUSION: While the iso-effect per fraction assumption would preclude the observation of adaptive responses for cells survival after radiotherapy fractions, this does not preclude the observation of adaptive responses for other endpoints. Adaptive responses for cell survival might also manifest without invalidating the iso-effect principle in practical terms. It may also be the case that instances of both phenomena can be observed under different conditions, but not at the same time. PMID: 29236558 [PubMed - as supplied by publisher]
CONCLUSIONS: The dynamic contrast-enhanced parameter of rate transfer constant from the fixed T1 acted as a preferable marker to differentiate true progression from pseudoprogression.
Accurate grading and staging are essential to ensure that men with prostate cancer are risk stratified correctly and thereby treated appropriately. In particular, high grade cancers are aggressively treated with surgery, high dose radiation therapy and years of androgen deprivation.1 These treatments are fortunately associated with higher cure rates but they may unfortunately negatively impact quality of life.
CONCLUSIONS: There exists a potential for microbleeds in patients treated with external beam radiation therapy without chemotherapy. This finding is of clinical relevance because it could be a precursor of future neurovascular disease and indicates that additional care should be taken when using therapies such as anticoagulants. Additionally, the appearance of venocentric WM lesions could be suggestive of a neuroinflammatory mechanism that has been suggested in diseases such as MS. Both findings merit further investigation in a larger population set.
The American Society of Radiation Oncology has recently recommended the use of radiosurgery to manage brain metastases. For such a recommendation to be implemented in a widespread manner, radiosurgery must be accessible at community radiation therapy facilities. The work presented here describes our clinical experience in the implementation of radiosurgery using a Helical TomoTherapy unit. Helical TomoTherapy is a unique dose-delivery system designed to perform intensity-modulated radiation therapy (IMRT).